Reproductive hormone transitions produce vulnerability windows where psychiatric symptoms cluster — premenstrual dysphoric disorder, pregnancy and postpartum mood disorders, perimenopausal and postmenopausal depression and anxiety. The biology is distinct from non-hormonally-driven depression and anxiety; the treatment frequently benefits from hormonal as well as psychiatric intervention. The longevity-psychiatry frame engages these windows directly, with attention to both immediate symptom management and the longer cognitive trajectory implications.
PMDD has discrete biology and treatment evidence. Cyclical depression, anxiety, irritability, and somatic symptoms in the luteal phase resolving with menses. Treatment options: SSRIs (luteal-phase or continuous), oral contraceptives (specific formulations), GnRH agonists with add-back, lifestyle interventions. SSRIs work rapidly in PMDD — within days of luteal-phase initiation — which is mechanistically distinct from depression treatment timeline. The recognition matters; many PMDD patients have been treated for major depression without addressing the cyclical pattern.
Postpartum depression and the broader postpartum spectrum. Postpartum depression has elevated incidence with major morbidity for mother and infant. Postpartum psychosis is an emergency requiring urgent treatment. Postpartum anxiety is common and underrecognized. Treatment options include SSRIs (sertraline well-studied in lactation), ECT for severe cases, the newer agents brexanolone and zuranolone (Stage 19.4) specifically for postpartum depression. Psychosocial interventions, sleep support, and family engagement are part of comprehensive treatment.
Perimenopausal depression has distinct features. Onset or recurrence of depression during the perimenopausal transition (typically ages 40s-50s); often presents with prominent anxiety, sleep disturbance, vasomotor symptoms alongside mood. Hormonal interventions — appropriate menopausal hormone therapy — frequently produce response when standard antidepressants alone have failed. The discipline is to consider hormonal context in perimenopausal depression rather than treating identical to non-hormonally-driven depression.
Postmenopausal mood and cognitive considerations. Some women experience persistent mood symptoms after menopause that respond to hormonal interventions; the cognitive longevity implications of hormonal optimization are discussed in Stage 19.6. The decision about menopausal hormone therapy involves balancing cardiovascular, cancer, and cognitive considerations against symptom severity; the conversation has evolved substantially with newer evidence on timing and formulations. The discipline is to recognize reproductive hormone transitions as discrete vulnerability windows, treat them with appropriate hormonal and psychiatric interventions, and coordinate care between psychiatry and reproductive endocrinology for comprehensive treatment.